6 mg implante en jeringa precargada

DRUG3 trials

Sponsors

Grupo Espanol De Investigacion En Cancer De Mama, Astrazeneca AB, Instituto De Investigacion En Oncología Radioterapica FEOR

Conditions

Patients with ER+ HER2- advanced breast cancer and patients with high-grade serious ovarian cancer (HGSOC)Patients with invasive breast cancer in early stagesProstate Cancer

Phase 1

A Phase I/IIa, First-in-human, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants with Selected Advanced or Metastatic Solid Tumors (CYCAD-1)

RecruitingCTIS2023-507305-33-00

Astrazeneca ABPatients with ER+ HER2- advanced breast cancer and patients with high-grade serious ovarian cancer (HGSOC)

Start: 2024-04-29Target: 28Updated: 2026-01-22

Phase 3

Short versus long-term androgen deprivation therapy combined with salvage radiotherapy in prostate cancer patients with biochemical recurrence after prostatectomy: a multicentre phase III randomised controlled trial

RecruitingCTIS2024-517666-41-00

Instituto De Investigacion En Oncología Radioterapica FEORProstate Cancer

Start: 2023-03-13Target: 534Updated: 2026-01-14

Phase 4

LONG-TERM FOLLOW-UP STUDY OF EARLY STAGE BREAST CANCER PATIENTS INCLUDED IN GEICAM STUDIES

RecruitingCTIS2022-502706-33-00

Grupo Espanol De Investigacion En Cancer De MamaPatients with invasive breast cancer in early stages

Start: 2018-01-10Target: 8000Updated: 2025-07-16